Foresite Capital


Foresite Capital is an American venture capital and growth equity firm. The company has offices in San Francisco and New York. As of May 2019, the company had raised four funds, Foresite Capital Fund I, II, III and IV.

History

Foresite Capital was founded in 2011 by Jim Tananbaum, co-founder of Theravance, who became CEO of the company.
Foresite Capital raised its $100 million Fund I in 2013. Foresite Capital has invested in companies such as Epizyme, Intarcia Therapeutics, Aerie Pharmaceuticals, Inscripta and Universal American. Foresite Capital funded 10x Genomics since its Series A round in November 2013 and led its Series B round in January 2015, as well as its Series C round in March 2016. In April 2014, Foresite Capital closed Foresite Capital Fund II, a $300 million fund. Foresite Capital Fund III, a $450 million fund, was closed in July 2015. Foresite Capital Fund IV, a $668 million fund, closed in March 2018.

Investments

Its investments include DNAnexus, Editas Medicine Immunomedics, Intarcia Therapeutics, Intellia Therapeutics, Juno Therapeutics, Turning Point Therapeutics, Natera, Orexigen, Pacific Biosciences, MindStrong, Relay Therapeutics,, Insitro, HealthVerity, Element Biosciences, and Portola Pharmaceuticals.
Foresite Capital is led by Midas List honoree Jim Tananbaum along with managing directors Matt Buten, Dorothy Margolskee, Brett Zbar, Dennis Ryan, and Vikram Bajaj.